NA-Semax Amidate
N-Acetyl-L-methionyl-L-glutamyl-L-histidyl-L-phenylalanyl-L-prolyl-glycyl-L-prolinamide (Ac-Met-Glu-His-Phe-Pro-Gly-Pro-NH2)
Investigational derivative of semax. Not FDA-approved or evaluated for compounding. Available as a research chemical.
A chemically stabilized version of Semax, a brain-protective peptide developed in Russia, modified to last longer in the body. No human trials exist for this specific form; its expected brain-protective and thinking-enhancement effects are based on studies of the original Semax compound.
This entry is a cited research summary, not an established treatment reference. Dosing language is included as source context, not as medical instruction.
NA-Semax Amidate is preclinical or hypothesis-only.
Investigational derivative of semax. Not FDA-approved or evaluated for compounding. Available as a research chemical.
Safety Summary
Direct NA-Semax Amidate safety data are sparse; all safety information below is derived from parent Semax clinical use in Russia and community reports. According to a review cited in the ADDF cognitive vitality report, the most common adverse events with Semax are nasal cavity discoloration (~10% of patients) and increased blood glucose in diabetics (~7.4% of patients) (Kolomin et al., 2013, review). No consistent reports of severe toxicity, organ damage, or dependence have been published (Swolverine review citing Russian prescribing data). Semax has been used safely in intranasal doses from 600 mcg/day to 12 mg/day for up to 30 days without major side effects (peptides.org review, references [25], [32], [33]). Community reports (online communities, forums) note appetite suppression, vivid dreams, improved mental clarity, and rare hair shedding. Side effects are generally dose-dependent and resolve upon discontinuation. Long-term safety data are limited.
Clinical check-in
If real-world use or exposure is being considered, review potential interactions, contraindications, and monitoring needs with a licensed clinician rather than relying on summary copy alone.
Cited sources
Every claim on this page links to one of the 12 sources below. Identifiers are PubMed (PMID), ClinicalTrials.gov (NCT), or DOI; click through to the source of record before acting on a claim.
- 1PMID 24661604PubMed
- 2PMID 16635254PubMed
- 3PMID 17353092PubMed
- 4PMID 19662538PubMed
- 5PMID 35080861PubMed
- 6PMID 25310602PubMed
- 7PMID 34201112PubMed
- 8PMID 32580520PubMed
- 9PMID 28255762PubMed
- 10PMID 40692165PubMed
- 11doi:10.1186/1471-2210-9-S2-A26DOI
- 12Meta-analysis: Semax effectiveness in the acute period of strokeReference